1 / 8

Evidence of the Month

BARI 2D methods/primary end points. Participants2368 with Type 2 diabetes and angiographically documented stable ischaemic heart diseaseMean age 62.4 years, 10.4 years average duration of diabetes, 32% with MI history, 30.7% with triple-vessel disease Randomization Either prompt revascularizati

karli
Télécharger la présentation

Evidence of the Month

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Evidence of the Month Comment on: A randomized trial of therapies for type 2 diabetes and coronary artery disease

    2. BARI 2D methods/primary end points Participants 2368 with Type 2 diabetes and angiographically documented stable ischaemic heart disease Mean age 62.4 years, 10.4 years average duration of diabetes, 32% with MI history, 30.7% with triple-vessel disease Randomization Either prompt revascularization or intensive medical therapy alone (delayed revascularization could take place if needed during the trial) and Either insulin-sensitizing therapy (mainly metformin and rosiglitazone) or insulin-providing therapy (sulfonylurea and insulin) End points Rate of death and major cardiovascular events (death, MI, or stroke) over 5 years

    3. Enrollment and randomization

    4. Survival outcomes: revascularization (CABG or PCI) vs medical therapy

    5. Survival outcomes: insulin sensitization vs insulin provision

    6. Freedom from major cardiovascular events: insulin sensitization vs insulin provision

    7. Freedom from major cardiovascular events: CABG vs medical therapy

    8. Clinical implications Prompt revascularization and intensive medical therapy alone offer comparable cardioprotection for individuals with Type 2 diabetes and stable ischaemic heart disease Insulin-providing and insulin-sensitizing glucose control strategies offer comparable cardioprotection; however, insulin sensitization is associated with lower HbA1c, less hypoglycaemia, lower plasma insulin, less weight gain, and higher high-density lipoprotein cholesterol Prompt CABG is associated with significantly greater cardioprotection than medical therapy alone, when CABG is needed; CABG/insulin-sensitizing therapy offers greatest protection Initial treatment with medication alone is a safe and effective option for most Type 2 diabetes patients with stable ischaemic heart disease BARI 2D reduces concerns about the cardiovascular safety of glucose control strategies and supports insulin sensitization and provision as reasonable treatment options

More Related